The present invention relates to a pharmaceutical composition or a functional food composition for preventing or treating a liver disease selected from the group consisting of steatohepatitis, hepatic fibrosis and cirrhosis. A triazole derivative compound discovered in the present invention reduces collagen accumulation in liver tissue and significantly inhibits the expression of inflammatory factors. Thus, the triazole derivative compound effectively blocks the progression of a series of severe liver diseases, from excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to a decrease in the number of hepatocytes and loss of liver function, unlike conventional drugs that have only a simple lipid-lowering effect. Accordingly, the triazole derivative compound may be useful as a composition for fundamental treatment of liver fibrosis and cirrhosis.

In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of pro teases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

A method of isolating barrel-like proteases is disclosed. The method comprising isolating barrel-like proteases from a biological sample containing the barrel-like proteases under conditions that maintain the content of the barrel-like protease-processed peptides in the barrel-like proteases upon isolation. A method of isolating barrel-like protease-processed peptides and a method of identifying barrel-like protease-processed peptides are also disclosed.

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

A method of isolating barrel-like proteases is disclosed. The method comprising isolating barrel-like proteases from a biological sample containing the barrel-like proteases under conditions that maintain the content of the barrel-like protease-processed peptides in the barrel-like proteases upon isolation. A method of isolating barrel-like protease-processed peptides and a method of identifying barrel-like protease-processed peptides are also disclosed.

The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition that modulate skin barrier permeability.

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

The present invention relates to a method of determining the gestational diabetic status of a pregnant subject, comprising providing a biological sample obtained from the subject; and determining the presence, and/or level, of syncytiotrophoblast extracellular vesicles, and/or insulin receptor, and/or DPPIV in the biological sample.

The present invention relates to antibodies, binding polypeptides, and scFvs specific for fibroblast activation protein (FAP) capable of cross reacting with canine, mouse, and human FAP.

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.